Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes

Exclusion Criteria

• •Combined Organ Transplantation
• •Age \< 18 years old
• •Pregnancy
• •Known allergy to prostaglandin (rare)
• •Refusal of blood products due to personal or religious preference
• •Subject is enrolled in another study protocol, which does not allow randomization of PVD therapy
• •Heart transplant or durable LVAD recipients with adult congenital heart disease (CHD)
• •Heart transplant recipients diagnosed with Arrythmogenic Right Ventricular Cardiomyopathy
• •Heart transplant recipients diagnosed with Acute Cardiac Allograft Rejection after a previous heart transplantation.
• •Heart transplant or durable LVAD recipients with preoperative RVAD for right heart failure
• •Patient is scheduled to undergo lung transplantation but has undergone heart transplantation in the previous 90 days
• •Patient is scheduled to undergo durable LVAD implantation but has undergone heart transplantation in the previous 90 days
• •Patient is scheduled to undergo heart transplantation but has undergone lung transplantation in the previous 90 days
• •Patients with preoperative Venovenous ECMO as a bridge to lung transplantation
• •Heart transplant or durable LVAD recipients with preoperative RVAD for right heart failure